November 7, 2021, Shanghai – HTDK Group and BD Medical, a Fortune 500 global leader in medical technology, successfully signed a strategic cooperation memorandum at the 2021 China International Import Expo (CIIE). Senior leaders from both companies held a cordial meeting, expressing their strong commitment and outlook for the future collaboration, which aims to co-develop the specialized market for BD’s Phasix hernia mesh and establish a new strategic partnership.

In 2020, third-party statistics indicated that over 1.4 million people in China suffer from inguinal and abdominal wall hernias, with an annual compound growth rate of approximately 6%. Current market offerings, such as permanent mesh products, carry a high risk of complications and potential for secondary surgeries, while biological meshes often lack the necessary strength, leading to hernia recurrence.

BD Medical’s innovative material technology offers a next-generation mesh product with a broader market potential in soft tissue repair, providing a promising solution for inguinal and abdominal wall hernia patients.

Through this strategic commercial partnership, HTDK will leverage its expertise in market access, in-depth channel development, and its customized, one-stop commercial solutions. Combining these capabilities with HTDK’s leading supply chain strengths and cutting-edge technology, the company will empower BD Medical to accelerate the commercialization of its innovative medical products in China. With more agile local decision-making, a proactive business model, and innovative services, the partnership aims to set new benchmarks in the industry and unlock significant potential in the medical device sector, driving further growth together.

Mr. Xueliang Zhu, Vice President of BD Medical Greater China’s Surgery Business Unit and Chairman of the China Market Committee, stated:

“Innovation is at the core of BD Medical’s DNA, and the upcoming launch of our mesh product represents a groundbreaking advancement. It has already been validated in the European and U.S. markets. As living standards continue to rise, more patients and doctors are looking to innovative mesh solutions to improve patients’ quality of life. Our partnership with HTDK is strategically significant, and we look forward to leveraging the strengths of both companies to accelerate innovation and deliver these benefits to more patients in China.”

HTDK CEO Teresa Chen commented:

“BD Medical holds the largest market share for mesh products in China, and with the upcoming launch of its innovative mesh solution, combined with its strong hospital partnerships and reputation, it is set to become a transformative force in hernia treatment. We are thrilled to form this strategic partnership at such a pivotal moment in the commercialization of BD’s mesh products. BD Medical’s vision of innovation and commitment to patient care aligns perfectly with HTDK’s mission. We look forward to providing comprehensive support and services to BD Medical, truly improving the lives of patients.”